A Study to Evaluate the Bioavailability of Fedratinib When Administered in Different Ways to Healthy Adult Participants

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit: www.BMSStudyConnect.com Inclusion Criteria: * Body Mass Index (BMI) of 18.0 to 33.0 kg/m\^2, inclusive. BMI = weight (kg)/(height \[m\])\^2 * Healthy based on medical history, physical examination, clinical laboratory test results, vital signs, and 12-lead electrocardiogram (ECG) at screening and check-in Exclusion Criteria: * Allergy to or hypersensitive to any of the drugs or nutritional supplement used in the study * Prior history of Wernicke's Encephalopathy * Thiamine deficiency * Hypersensitivity to ondansetron * Has any medical condition, medical history, or use of concomitant medication that is contraindicated in the applicable drug labeling * Has history, deviated nasal septum, and/or obstructed airway, bleeding disorders, or other inabilities for insertion of nasogastric (NG) tube (Part 2 only) Other protocol-defined inclusion/exclusion criteria apply